Document is current
Any future updates will be listed below
-
Authors
Xia, Peiyi
Yang, Huan
Yu, Pu
Miao, Yu
Tang, Longfei
Wang, Yuqiang
Li, Binghui
Wang, Zeyuan
Jiang, Guozhong
Chen, Kuisheng
Li, Shenglei
Yang, Minglei
-
Funding
Funding for this research was provided by:
the National Natural Science Foundation of China (62402207)
the National Natural Science Foundation of China (82172941)
the National Natural Science Foundation of China (32500560)
Henan Province Natural Science Foundation (252300421598)
- License Information
-
More Information
Article History
Received: 9 June 2025
Accepted: 2 March 2026
First Online: 14 March 2026
Competing interests
: The First Affiliated Hospital of Zhengzhou University has filed a pending patent application related to this work (Application Number: 202511022293.8; Status: Substantive examination stage; Filed: September 26, 2025; Title: “Biological Markers for Predicting Melanoma Response to Immunotherapy and Their Application"; Applicant: The First Affiliated Hospital of Zhengzhou University; Inventors: Minglei Yang, Peiyi Xia; Coverage: Use of CD27 as a predictive biomarker for melanoma immunotherapy response). The other authors declare no competing financial or non-financial interests.
